[go: up one dir, main page]

DK200001556A - Substituerede thiazolidindionderivater - Google Patents

Substituerede thiazolidindionderivater Download PDF

Info

Publication number
DK200001556A
DK200001556A DK200001556A DKPA200001556A DK200001556A DK 200001556 A DK200001556 A DK 200001556A DK 200001556 A DK200001556 A DK 200001556A DK PA200001556 A DKPA200001556 A DK PA200001556A DK 200001556 A DK200001556 A DK 200001556A
Authority
DK
Denmark
Prior art keywords
thiazolidinedione
methyl
ethoxy
amino
group
Prior art date
Application number
DK200001556A
Other languages
English (en)
Inventor
Hindley Richard Mark
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27263577&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK200001556(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB878720825A external-priority patent/GB8720825D0/en
Priority claimed from GB878727987A external-priority patent/GB8727987D0/en
Priority claimed from GB888802454A external-priority patent/GB8802454D0/en
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Publication of DK200001556A publication Critical patent/DK200001556A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Description

PATENTKRAV 1. Forbindelse med formlen (I):
Figure DK200001556AD00031
eller en tautomer form deraf, og/eller et farmaceutisk acceptabelt salt deraf, og/eller et farmaceutisk acceptabelt solvat deraf, kendetegnet ved, at betegner en substitueret eller usubstitueret aromatisk hetero-cyclylgruppe; r! betegner et hydrogenatom, en alkylgruppe, en acylgruppe, en aral-kylgruppe, hvor arylgruppen kan være substitueret eller usubstitueret, eller en substitueret eller usubstitueret arylgruppe; og betegner hver hydrogen, eller R^ og R^ betegner tilsammen en binding; A^ betegner en benzenring med i alt op til 5 substituenter; og n betegner et helt tal i området fra 2 til 6. 1
Forbindelse ifølge krav 1, kendetegnet ved, at A^ betegner en substitueret eller usubstitueret, enkelt- eller kondenseretring aromatisk heterocyclyl-gruppe omfattende op til A heteroatomer i ringen valgt blandt oxygen, svovl og nitrogen, fx betegner A1 en gruppe med formlen (a), (b) eller (c):
Figure DK200001556AD00032
hvor: R4 og R1 hver uafhængigt af hinanden betegner et hydrogenatom, en alkylgruppe eller en substitueret eller usubstitueret arylgruppe, fx en substitueret eller usubstitueret phenylgruppe, eller, når R^ og hver er bundet til et carbonatom, danner R^ og R^ sammen med de carbonatomer, hvortil de er bundet, en benzenring, hvor hvert carbonatom, der er betegnet ved R^ og R^, sammen kan være substitueret eller usubstitueret, fx betegner R^ og R-> sammen en gruppe med formlen (d):
Figure DK200001556AD00041
(d) hvor R® og R^ hver uafhængigt af hinanden betegner hydrogen, halogen, substitueret eller usubstitueret alkyl eller alkoxy, fx betegner R® og R^ begge hydrogen; og i gruppen med formlen (a) betegner X oxygen eller svovl. 3. Forbindelse ifølge krav 1 eller 2, kendetegnet ved, at betegner en gruppe med formlen (e) :
Figure DK200001556AD00042
(e) hvor R® og R^ hver uafhængigt af hinanden betegner hydrogen, halogen, substitueret eller usubstitueret alkyl eller alkoxy, fx en forbindelse, hvor R® og R^ hver betegner hydrogen. 64 4. Forbindelse ifølge krav 1, med formlen (II):
Figure DK200001556AD00051
eller en tautomer form deraf og/eller et farmaceutisk acceptabelt salt deraf og/eller et farmaceutisk acceptabelt solvat deraf, kendetegnet ved, at A*, R*-, R^, R^ og n er som defineret i forbindelse med formlen (I) i krav 1, og R® og er som defineret i forbindelse med formlen (e) i krav 3. 5. Forbindelse ifølge et hvilket som helst af kravene 1 til 4, kendetegnet ved, at n betegner et helt tal 2 eller 3, og/eller at R* betegner en methylgruppe. 6. Forbindelse ifølge krav 1, valgt fra listen bestående af: 5-(4-(2-(N-methyl-N-(2-benzothiazolyl)amino)ethoxy]benzyl)-2,4-thia-zolidindion; 5-(4-[2-(N-methyl-N-(2-benzothiazolyl)amino)ethoxy]benzyliden) -2 ,4-thiazolidindion; 5-(4-[2-(N-methyl-N-(2-benzoxazolyl)amino)ethoxy]benzyl)-2,4-thiazo-lidindion; 5-(4-[2-(N-me thyl - N - ( 2 -benzoxazo ly 1) amino ) e thoxy ] benzyl iden) -2,4-thiazolidindion; 1 (4- [2- (N-methyl-N- (2-pyrimidinyl)amino)ethoxy]benzyl) -2,4-thiazoli-dindion; 5-(4-[2-(N-methyl-N-(2-pyrimidinyl)amino)ethoxy]benzyliden)-2,4- thiazolidindion; 5-(4-(2-(N-methyl-N-[2-(4,5-dimethylthiazolyl)]amino)ethoxy]benzyl) - 2.4- thiazolidindion; 5-(4-[2-(N-methyl-N-[2-(4,5-dimethylthiazolyl)]amino)ethoxy]benzyli-den)-2,4-thiazolidindion; 5-(4-(2-(N-methyl-N-(2-thiazolyl)amino) ethoxy]benzyl)-2,4-thiazolidindion; 5-(4-[2-(N-methyl-N-(2-thiazolyl)amino)ethoxy]benzyliden)-2,4-thiazolidindion; 5-[4-(2-(N-methyl-N-(2-(4-phenylthiazolyl))amino)ethoxy)benzyl]-2,4-thiazolidindion; 5-(4-[2-(N-methyl-N-(2-(4-phenylthiazolyl))amino)ethoxy]benzyliden)- 2.4- thiazolidindion; 5-(4-(2-(N-methyl-N-[2-(4-phenyl-5-methylthiazolyl)]amino)ethoxy]benzyl) -2,4-thiazolidindion; 5-(4-[2-(N-methyl-N-(2-(4-phenyl-5-methylthiazolyl)]amino)ethoxy]ben -zyliden)-2,4-thiazolidindion; 5-(4-[2-(N-methyl-N-[2-(4-methyl-5-phenylthiazolyl)]amino)ethoxy]ben-zyl)-2,4-thiazolidindion; 5- (4-[2-(N-methyl-N-[2-(4-methyl-5-phenylthiazolyl)]amino)ethoxy]ben-zyliden)-2,4-thiazolidindion; 5-(4-[2-(N-methyl-N-[2-(4-methylthiazolyl)]amino)ethoxy]benzyl)-2,4-thiazolidindion; 5-(4-[2-(N-methyl-N-[2-(4-methylthiazolyl)]amino)ethoxy]benzyl iden)- 2.4- thlazol tdlnd-J on : 5-[4-(2-(N-methyl-N-[2-(5-phenyloxazolyl)]amino)ethoxy)benzyl]-2,4- thiazolidlndion; 5-(4-[2-(N-methyl-N-[2-(5-phenyloxazolyl)]amino)ethoxy]benzyliden)- 2.4- thlazolidindlon; 5-(4-[2-(N-methyl-N-[2-(4,5-dimethyloxazolyl)]amino)ethoxy]benzyl)- 2.4- thiazolidindion; 5-(4-[2-(N-methyl-N-[2-(4,5-dimethyloxazolyl)]amino)ethoxy]benzyli-den)-2,4-thiazolidindion; 5-[4-(2-(2-pyrimidinylamino)ethoxy)benzyl]-2,4-thiazolidindion; 5-[4-(2-(2-pyrimidinylamino)ethoxy)benzyliden]-2,4-thiazolidindion; 5-(4-[2-(N-acetyl-N-(2-pyrimidinyl)amino)ethoxy]benzyl)-2,4-thiazolidindion; 5-(4-(2-(N-(2-benzothiazolyl)-N-benzylamino)ethoxy)benzyliden)-2,4-thiazolidindion; 5-(4-(2-(N-(2-benzothiazolyl)-N-benzylamino)ethoxy)benzyl)-2,4-thiazolidindion; 5-(4-[3-(N-methyl-N-(2-benzoxazolyl)amino)propoxy]benzyl)-2,4-thiazolidindion; 5-(4-(3-(N-methyl-N-(2-benzoxazolyl)amino)propoxy]benzyliden)-2,4-thiazolidindion; 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidin-dion; og 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxyjbenzyliden)-2,4-thiazolidindion; eller en tautomer form deraf, og/eller et farmaceutisk acceptabelt salt deraf, og/eller et farmaceutisk acceptabelt solvat deraf. 7. Fremgangsmåde til fremstilling af en forbindelse med formlen (I), eller en tautomer form deraf, og/eller et farmaceutisk acceptabelt salt deraf, og/eller et farmaceutisk acceptabelt solvat deraf, kendetegnet ved, at enten (a) en forbindelse med formlen (III)
Figure DK200001556AD00081
(III) hvor R^, og er som defineret i forbindelse med formlen (I), og Ra er en gruppe, der kan omdannes til en gruppe med formlen (f):
Figure DK200001556AD00082
(f) hvor R*·, A*· og n er som defineret i forbindelse med formlen (I), omsættes med et egnet reagens, der er i stand til at omdanne Ra til gruppen (f); eller (b) en forbindelse med formlen (VIII):
Figure DK200001556AD00083
(VIII) hvor R^, A^, A^ og n er som defineret i forbindelse med formel (I), omsættes med 2,4-thiazolidindion; og derefter, om nødvendigt, at ét eller flere af følgende eventuelle trin udføres: (i) en forbindelse med formlen (I) omdannes til en anden forbindelse med formlen (I); (ii) et farmaceutisk acceptabelt salt af forbindelsen med formlen (1) og/eller et farmaceutisk acceptabelt solvat deraf fremstilles. 8. Farmaceutisk præparat, kendetegnet ved, at det omfatter en forbindelse med formlen (I) ifølge krav 1, eller en tautomer form deraf, eller et farmaceutisk acceptabelt salt deraf eller farmaceutisk acceptabelt solvat deraf, og en farmaceutisk acceptabel bærer dertil. 9. Forbindelse med formlen (I) ifølge krav 1, eller en tautomer form deraf, og/eller et farmaceutisk acceptabelt salt deraf, og/eller et farmaceutisk acceptabelt solvat deraf, kendetegnet ved, at den anvendes som en aktiv terapeutisk bestanddel, fx til behandling af og/eller profylakse af hyperglykæmi og/eller hyperlipidæini. 10. Anvendelse af en forbindelse med formlen (I) ifølge krav 1, eller en tautomer form deraf, og/eller et farmaceutisk acceptabelt salt deraf, og/eller et farmaceutisk acceptabelt solvat deraf til fremstilling af et medikament til behandling og/eller profylakse af hyperglykæmi og/eller hyperlipidæmi.
DK200001556A 1987-09-04 2000-10-18 Substituerede thiazolidindionderivater DK200001556A (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB878720825A GB8720825D0 (en) 1987-09-04 1987-09-04 Compounds
GB878727987A GB8727987D0 (en) 1987-11-30 1987-11-30 Novel compounds
GB888802454A GB8802454D0 (en) 1988-02-04 1988-02-04 Compounds

Publications (1)

Publication Number Publication Date
DK200001556A true DK200001556A (da) 2000-10-18

Family

ID=27263577

Family Applications (2)

Application Number Title Priority Date Filing Date
DK198804902A DK175176B1 (da) 1987-09-04 1988-09-02 Forbindelsen 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidindion, et farmaceutisk præparat indeholdende forbindelsen, forbindelsen som en aktiv terapeutisk bestanddel og anvendelsen af forbindelsen til fremstilling af et medikament
DK200001556A DK200001556A (da) 1987-09-04 2000-10-18 Substituerede thiazolidindionderivater

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK198804902A DK175176B1 (da) 1987-09-04 1988-09-02 Forbindelsen 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidindion, et farmaceutisk præparat indeholdende forbindelsen, forbindelsen som en aktiv terapeutisk bestanddel og anvendelsen af forbindelsen til fremstilling af et medikament

Country Status (19)

Country Link
US (1) US5002953A (da)
EP (2) EP0306228B1 (da)
JP (6) JP2614497B2 (da)
KR (1) KR0164207B1 (da)
AT (1) ATE186724T1 (da)
AU (1) AU611938B2 (da)
CA (1) CA1328452C (da)
CZ (1) CZ391691A3 (da)
DE (2) DE3856378T2 (da)
DK (2) DK175176B1 (da)
ES (1) ES2137915T3 (da)
GR (1) GR3031873T3 (da)
HK (1) HK1011029A1 (da)
IE (1) IE20000683A1 (da)
LU (1) LU90711I2 (da)
NL (1) NL300034I2 (da)
NZ (1) NZ226027A (da)
PT (1) PT88410B (da)
SG (1) SG59988A1 (da)

Families Citing this family (274)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194443A (en) * 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group P.L.C., Brentford Substituierte Thiazolidindionderivate
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB8919417D0 (en) 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
US5053420A (en) * 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
US5037842A (en) * 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
GB9017218D0 (en) * 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023584D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
EP0715853A1 (en) * 1991-01-10 1996-06-12 Transcend Therapeutics, Inc. Use of glutathione esters for the treatment of pulmonary diseases
US5747459A (en) * 1991-02-04 1998-05-05 Nestec, Ltd. Method for insuring adequate intracellular glutathione in tissue
JP3053490B2 (ja) * 1991-02-25 2000-06-19 杏林製薬株式会社 チアゾリジン−２，４−ジオン誘導体とその塩及び製造法
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
US5589492A (en) * 1992-04-10 1996-12-31 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of Type-II diabetes
WO1993021166A1 (en) * 1992-04-10 1993-10-28 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type ii-diabetes
US5430045A (en) * 1992-04-23 1995-07-04 Free Radical Sciences, Inc. Method of reducing or preventing bone marrow hypoplasia
US6048883A (en) * 1992-07-03 2000-04-11 Smithkline Beecham P.L.C. Heterocyclic compounds as pharmaceutical
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
US5306724A (en) * 1992-08-17 1994-04-26 Clintec Nutrition Company Method for preventing and treating atherosclerosis
DE69326736T2 (de) * 1992-08-31 2000-06-08 Sankyo Co., Ltd. Oxazolidin-Derivate mit Antidiabetika und Anti-Fettleibigkeit-Eigenschaften, ihre Herstellung und therapeutische Verwendung
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
AU668818B2 (en) * 1993-04-07 1996-05-16 Taiho Pharmaceutical Co., Ltd. Thiazolidine derivative and pharmaceutical composition containing the same
GB9308487D0 (en) * 1993-04-23 1993-06-09 Smithkline Beecham Plc Novel compounds
GB9311644D0 (en) * 1993-06-05 1993-07-21 Smithkline Beecham Plc Novel compounds
GB9311661D0 (en) * 1993-06-05 1993-07-21 Smithkline Beecham Plc Novel compounds
GB9315148D0 (en) * 1993-07-22 1993-09-08 Smithkline Beecham Plc Novel compounds
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
ATE376829T1 (de) * 1993-09-15 2007-11-15 Daiichi Sankyo Co Ltd Verwendung von thiazolidindionen zur vorbeugung oder verzögerung des auftretens des nichtinsulinabhängigen diabetes mellitus (niddm)
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5447712A (en) * 1993-12-09 1995-09-05 Free Radical Sciences Method of reducing cyclophosphamide induced hemorrhagic cystitis
US5480896A (en) * 1994-01-27 1996-01-02 American Home Products Corporation Aralkyl-1,2,4-oxadiazolidine-3,5-diones as antihyperglycemic agents
EP0777469A1 (en) * 1994-02-10 1997-06-11 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
IL113313A (en) * 1994-04-11 1999-09-22 Sankyo Co Heterocyclic compounds and pharmaceutical compositions containing the same
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
CA2159938A1 (en) * 1994-10-07 1996-04-08 Hiroaki Yanagisawa Oxime derivatives, their preparation and their therapeutic use
US5436373A (en) * 1994-10-26 1995-07-25 Elf Atochem North America, Inc. Process for the preparation of N-benzyl-N-organoaminoalkanol
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
US5827865A (en) * 1995-03-09 1998-10-27 Smithkline Beecham P.L.C. Heterocyclic compounds as pharmaceutical
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
IL118474A (en) * 1995-06-01 2001-08-08 Sankyo Co Benzimideol derivatives and pharmaceutical preparations containing them
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
RU2158607C2 (ru) * 1995-07-03 2000-11-10 Санкио Компани Лимитед Лечение артериосклероза и ксантомы
US6020382A (en) * 1996-02-02 2000-02-01 Merck & Co., Inc. Method of treating diabetes and related disease states
US6090836A (en) * 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
US5847008A (en) * 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
KR20000005224A (ko) * 1996-04-04 2000-01-25 가와무라 요시부미 페닐알킬카르복실산 유도체_
ATE231136T1 (de) * 1996-04-09 2003-02-15 Reddys Lab Ltd Dr Thiazolidinedionderivate mit antidiabetischen, hypolipidämischen und antihypertensiven eigenschaften, verfahren zu deren herstellung und pharmazeutischen zusammenstellungen, die sie enthalten
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5889025A (en) * 1996-05-06 1999-03-30 Reddy's Research Foundation Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
WO1997043283A1 (de) * 1996-05-16 1997-11-20 Boehringer Mannheim Gmbh Neues verfahren zur herstellung von troglitazone
CA2257284C (en) * 1996-05-31 2005-10-04 Sankyo Company Limited Remedy for autoimmune diseases
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
US5985884A (en) * 1996-07-01 1999-11-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
JP2000514041A (ja) * 1996-07-26 2000-10-24 ドクター・レディーズ・リサーチ・ファウンデーション 抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
UY24886A1 (es) * 1997-02-18 2001-08-27 Smithkline Beecham Plc Tiazolidindiona
AU774839B2 (en) * 1997-02-18 2004-07-08 Smithkline Beecham Plc Process for the preparation of substituted thiazolidinedione
DE69838789T2 (de) * 1997-03-12 2008-10-30 Suzanne Cambridge de la Monte Verfahren zur behandlung oder prävention der alzheimerischen krankheit
DE19711616A1 (de) * 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6011036A (en) * 1997-04-15 2000-01-04 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them
US6011031A (en) * 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
TR199903057T2 (xx) * 1997-06-18 2000-04-21 Smithkline Beecham Plc Diabetin tiazolidinedion ve metformin ile tedavisi.
UA67743C2 (uk) * 1997-06-18 2004-07-15 Смітклайн Бічам П.Л.С. Фармацевтична композиція, що містить тіазолідиндіон і сульфонілсечовину, для лікування діабету
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
CA2305808A1 (en) 1997-10-02 1999-04-15 Sankyo Company Limited Amidocarboxylic acid derivatives
US20010031776A1 (en) * 1997-10-13 2001-10-18 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
GB9721693D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
GB9723295D0 (en) * 1997-11-04 1998-01-07 Smithkline Beecham Plc Novel process
US7091359B2 (en) 1997-11-04 2006-08-15 Smithkline Beecham Plc Process for the preparation of thiazolidinedione derivatives
HUP9902721A2 (hu) 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
WO1998045292A1 (en) * 1997-12-02 1998-10-15 Dr. Reddy's Research Foundation Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypolipidaemic and antihypertensive properties
AU7109798A (en) * 1997-12-02 1998-10-30 Dr. Reddy's Research Foundation Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypol ipidemia and antihypertensive properties
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
AU1507799A (en) * 1997-12-16 1999-07-05 Sankyo Company Limited Leukemia remedy
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726563D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6489344B1 (en) 1998-06-19 2002-12-03 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6613785B2 (en) 1998-07-21 2003-09-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
WO2000004890A1 (en) * 1998-07-21 2000-02-03 Smithkline Beecham P.L.C. Use of glucose uptake enhancer for reducing apoptosis
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation
IN187716B (da) * 1998-09-14 2002-06-15 Reddy Research Foundation
AR023700A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
TR200101333T2 (tr) 1998-11-12 2001-10-22 Smithkline Beecham P.L.C. Bir ensülin sensitizörü ve başka bir anti-diyabetik maddenin değiştirilmiş salımı için farmasötik terkip.
AU1740900A (en) * 1998-11-20 2000-06-13 Genentech Inc. Method of inhibiting angiogenesis
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
AU3073700A (en) * 1999-01-19 2000-08-07 Sankyo Company Limited Troglitazone-containing medicinal compositions for inhibiting apoptosis
GB9909075D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
PL351685A1 (en) * 1999-04-23 2003-06-02 Smithkline Beecham Plc Novel pharmaceutical
OA11871A (en) 1999-04-23 2006-03-27 Smithkline Beecham Plc Novel pharmaceutical.
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
MXPA01010821A (es) 1999-04-23 2003-09-04 Smithkline Beecham Plc Forma poliformica de sal de acido maleico de 5-[4-[2 -(n-metil -n-(2- piridil) amino ) etoxi] bencil ] tiazolidin-2, 4-diona.
DE60035271D1 (en) 1999-04-28 2007-08-02 Inst Med Molecular Design Inc Pyrimidincarbonsäurederivate
GB9913782D0 (en) * 1999-06-14 1999-08-11 Smithkline Beecham Plc Novel compounds
EP1194147B1 (en) * 1999-06-18 2007-01-10 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
HUP0202438A2 (hu) * 1999-08-17 2002-12-28 Smithkline Beecham Plc. Dioxo-tiazolidin-származékok és ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
AR028299A1 (es) 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
ES2156574B1 (es) 1999-11-18 2002-02-01 Vita Invest Sa Nuevos derivados de tiazolidindiona como agentes antidiabeticos
MXPA02005528A (es) 1999-12-03 2002-09-02 Kyoto Pharma Ind Compuestos heterociclicos sus sales y uso medicinal.
HU225919B1 (en) * 1999-12-18 2007-12-28 Richter Gedeon Nyrt Thiazolidine-derivatives, process for their preparation pharmaceutical and intermediates
CN1400908A (zh) 2000-01-21 2003-03-05 诺瓦提斯公司 含有二肽基肽酶－iv抑制剂的联合形式
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
US6958355B2 (en) 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6768008B2 (en) 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6784199B2 (en) 2000-09-21 2004-08-31 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals
EP1284291A4 (en) * 2000-05-25 2005-06-08 Yamanouchi Pharma Co Ltd PROMOTER OF HUMAN PGC-1
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0019223D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
IL155036A0 (en) * 2000-09-26 2003-10-31 Reddy Research Foundation Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] benzyl] thiazolidine-2,4-dione maleate and pharmaceutical compositions containing the same
US7241895B2 (en) 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
GB0023971D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
GB0029125D0 (en) * 2000-11-29 2001-01-10 Specialistkliniken I Varberg H Novel treatment
ATE337313T1 (de) 2000-12-22 2006-09-15 Smithkline Beecham Plc 5-4'-2'-(n-methyl-n-(2-pyridyl)amino) ethoxy)benzyl)thiazolidin-2,4-dion mesylatsalz
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
WO2002051823A1 (en) 2000-12-26 2002-07-04 Torrent Pharmaceuticals Ltd Process for the preparation of rosiglitazone maleate
WO2002051441A1 (fr) * 2000-12-26 2002-07-04 Sankyo Company, Limited Compositions medicinales contenant un diuretique et un agent renforçant la resistance a l'insuline
ES2174748B1 (es) * 2001-01-31 2003-09-16 Vita Lab Nueva sal de tiazolidindiona y sus polimorfos como agentes antidiabeticos y procedimiento para la obtencion de los mismos.
US20030045553A1 (en) * 2001-04-04 2003-03-06 Bussolari Jacqueline C. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
US20060047000A1 (en) * 2001-04-24 2006-03-02 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6872732B2 (en) * 2001-05-29 2005-03-29 Kyoto Pharmaceutical Industries, Ltd. Heterocyclic derivatives and medicinal use thereof
PL367639A1 (en) * 2001-05-29 2005-03-07 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic compound and medicinal use thereof
JP4152641B2 (ja) * 2001-08-07 2008-09-17 クラシエ製薬株式会社 チアゾリジン誘導体の副作用軽減剤
WO2003029251A1 (en) * 2001-09-28 2003-04-10 Biocon Limited Novel process for the synthesis of thiazolidinedione derivatives
GB0127805D0 (en) 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002352391A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
GB0129872D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129851D0 (en) * 2001-12-13 2002-01-30 Smithkline Beecham Plc Novel compounds
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0130511D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130510D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
CA2470075A1 (en) * 2001-12-20 2003-07-03 Teva Pharmaceutical Industries Ltd. Hydrogenation of precursors to thiazolidinedione antihyperglycemics
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002352479A1 (en) * 2001-12-20 2003-07-09 Smithkline Beecham Plc 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
US7015345B2 (en) * 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
KR100450700B1 (ko) 2002-03-22 2004-10-01 주식회사종근당 티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
PT1474417E (pt) * 2002-04-29 2006-06-30 Teva Pharma Processos para preparacao de losartan e losartan potassico
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
EP1388352A1 (en) 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2004089945A1 (en) * 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Rosiglitazone derivatives as antidiabetic agents
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
JPWO2004106542A1 (ja) * 2003-05-29 2006-07-20 三共株式会社 インスリン抵抗性改善剤及びそのスクリーニング方法
MXPA05012900A (es) * 2003-05-30 2006-02-22 Ranbaxy Lab Ltd Derivados de pirrol sustituidos.
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
US20050070531A1 (en) 2003-08-13 2005-03-31 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2005023803A1 (en) * 2003-09-10 2005-03-17 Biocon Limited Phosphoric acid salt of 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl] methyl]- 2,4-thiazolidinedione
WO2005027967A1 (ja) * 2003-09-17 2005-03-31 Kaname Kawasugi 医薬組成物
WO2005065663A1 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone and metformin formulations
US20050163837A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone formulations
EP1709038A2 (en) * 2004-01-28 2006-10-11 Usv Limited A process for the preparation of 5- 4- 2- n-methyl -n-(2-pyridyl) amino ethoxy phenyl methyl thiaz olidine-2, 4-dione maleate
GB2410948A (en) * 2004-02-13 2005-08-17 Sandoz Ag Novel phosphoric acid salt of rosiglitazone
GB2421240A (en) * 2004-12-14 2006-06-21 Sandoz Ag Phosphoric acid salt of rosiglitazone
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
CN102134229B (zh) * 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
BRPI0509305A (pt) * 2004-03-29 2007-09-04 Sankyo Co uso de um sensibilizador insulìnico, composição farmecêutica, e , kit
GB2413795A (en) * 2004-05-05 2005-11-09 Cipla Ltd Process for the preparation of rosiglitazone
EP1745043A1 (en) * 2004-05-12 2007-01-24 Medichem S.A. Process for the preparation of rosiglitazone
CZ296468B6 (cs) * 2004-06-10 2006-03-15 Zentiva, A. S. Sul kyseliny fosforecné s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionema zpusob její prípravy
TW200608967A (en) * 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
CZ297266B6 (cs) * 2004-09-10 2006-10-11 Zentiva, A. S. Zpusob prípravy rosiglitazonu
CZ297347B6 (cs) * 2004-09-21 2006-11-15 Zentiva, A. S. Zpusob prípravy rosiglitazonu
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
US20070190079A1 (en) * 2004-10-29 2007-08-16 Kalypsys, Inc. Methods for the selective modulation of ppar
US20060122232A1 (en) * 2004-12-06 2006-06-08 Development Center For Biotechnology 4-Hydroxyfuroic acid derivatives
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
US20070269486A1 (en) * 2005-03-14 2007-11-22 Conor Medsystems, Llc. Methods and Devices for Reducing Tissue Damage After Ischemic Injury
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
FR2887442A1 (fr) * 2005-06-28 2006-12-29 Oreal Composes benzyl-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute
FR2887444A1 (fr) * 2005-06-28 2006-12-29 Oreal Composes benzylidene-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute et/ou augmenter leur densite.
EP1905450A1 (en) * 2005-07-12 2008-04-02 Daiichi Sankyo Company, Limited Pharmaceutical composition containing ppar gamma agonist
WO2007033350A1 (en) * 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
CN101360723A (zh) * 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
TW200730173A (en) * 2005-12-16 2007-08-16 Sankyo Co Pharmaceutical composition enhancing production of adiponectin
US20090234128A1 (en) * 2006-03-08 2009-09-17 Ernesto Duran Lopez Process for the Preparation of Intermediates of Rosiglitazone, Rosiglitazone and New Polymorphic Forms Thereof
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
US20100029941A1 (en) * 2006-03-28 2010-02-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
CA2647258A1 (en) * 2006-03-31 2007-10-18 Wellstat Therapeutics Corporation Combination treatment of metabolic disorders
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
DE202006020710U1 (de) 2006-05-09 2009-12-31 Teva Pharmaceutical Industries Ltd. Zusammensetzungen mit Rosiglitazonmaleat
US20070293546A1 (en) * 2006-06-15 2007-12-20 Srinivasula Reddy Maddula Preparation of rosiglitazone and its salts
HUP0600517A3 (en) * 2006-06-23 2008-10-28 Richter Gedeon Nyrt Process for the production of benzylidene-rosiglitazone base
AU2007265475B2 (en) 2006-06-26 2010-08-19 Amgen Inc. Methods for treating atherosclerosis
CL2007002044A1 (es) * 2006-07-14 2008-06-13 Ranbaxy Lab Ltd Polimorfo cristalino de la sal hemicalcica del acido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3,5-dihidroxiheptanoico; composicion farmaceutica; y uso para el tratamiento de la diabetes, enf
JP2010502670A (ja) 2006-09-07 2010-01-28 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 真性糖尿病のための組合せ治療
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
MY145447A (en) * 2006-09-13 2012-02-15 Takeda Pharmaceutical Use of 2-6(3-amino-piperidin-1-yl)-3-methyl-2, 4-dioxo-3, 4-dihydrp-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
EP2114404A4 (en) 2006-12-21 2010-03-03 Alphapharm Pty Ltd COMPOUND AND PHARMACEUTICAL COMPOSITION
US20080176905A1 (en) * 2007-01-22 2008-07-24 Santiago Ini Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
CA2677661A1 (en) 2007-02-07 2008-08-14 Kyowa Hakko Kirin Co., Ltd. Tricyclic compounds
US8093236B2 (en) * 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
JP5294419B2 (ja) 2007-04-05 2013-09-18 第一三共株式会社 縮合二環式ヘテロアリール誘導体
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
UA103304C2 (ru) 2007-07-26 2013-10-10 Эмджен Инк. Модифицированный белок лецитин-холестерин ацилтрансферазы (lcat)
US20090076093A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched rosiglitazone
PL384446A1 (pl) * 2008-02-12 2009-08-17 Adamed Spółka Z Ograniczoną Odpowiedzialnością Sól 5-[[4-[2-(metylo-2-pirydynyloamino)etoksy]fenylo]metylo]-2,4-tiazolidynodionu z kwasem malonowym i sposób jej wytwarzania
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP3081213B1 (en) 2008-08-06 2020-04-01 Kyowa Kirin Co., Ltd. Tricyclic compound
PE20150362A1 (es) 2008-08-12 2015-03-20 Zinfandel Pharmaceuticals Inc Metodo de identificacion de factores de riesgo de la enfermedad
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate
US20100144140A1 (en) * 2008-12-10 2010-06-10 Novellus Systems, Inc. Methods for depositing tungsten films having low resistivity for gapfill applications
HUP0800755A2 (en) 2008-12-11 2010-09-28 Richter Gedeon Nyrt Crystalline forms of rosiglitazone
ES2617191T3 (es) 2009-03-05 2017-06-15 Daiichi Sankyo Company, Limited Derivado de piridina como inhibidor de PPARY
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
EP2552442A1 (en) 2010-03-30 2013-02-06 Boehringer Ingelheim International GmbH Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
JPWO2012033091A1 (ja) 2010-09-07 2014-01-20 第一三共株式会社 安息香酸エステル類の製造法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
CA2824050A1 (en) 2011-01-10 2012-07-19 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating alzheimer's disease
WO2013018899A1 (ja) 2011-08-03 2013-02-07 協和発酵キリン株式会社 ジベンゾオキセピン誘導体
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
TW201329104A (zh) 2011-12-08 2013-07-16 Amgen Inc 人類ｌｃａｔ抗原結合蛋白質及其治療用途
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
JP6453224B2 (ja) 2012-11-05 2019-01-16 コミッサリア ア レネルジ アトミック エ オー エネルジス アルテルナティヴスＣｏｍｍｉｓｓａｒｉａｔ Ａ Ｌ‘Ｅｎｅｒｇｉｅ Ａｔｏｍｉｑｕｅ Ｅｔ Ａｕｘ Ｅｎｅｒｇｉｅｓ Ａｌｔｅｒｎａｔｉｖｅｓ インビボで血液がんの幹細胞を排除するため、および血液がんの再発を防ぐための、チロシンキナーゼ阻害剤のような抗がん剤と、好ましくはチアゾリジンジオンであるｓｔａｔ５アンタゴニストとの組み合わせ
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
ES2981866T3 (es) 2013-06-05 2024-10-10 Bausch Health Ireland Ltd Agonistas ultrapuros de guanilato ciclasa C, método de elaboración y uso de los mismos
AU2014331812B2 (en) 2013-10-09 2019-01-17 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
EP3065723B1 (en) 2013-11-05 2020-09-23 Ben Gurion University of the Negev Research and Development Authority Compounds for the treatment of diabetes and disease complications arising from same
MX2017004947A (es) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
US10034868B2 (en) 2014-11-04 2018-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
WO2018130679A1 (en) 2017-01-16 2018-07-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing cd95- mediated cell motility
GR1010570B (el) * 2022-12-22 2023-11-17 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Α.Β.Ε.Ε., 4-(2-(4-((2,4-διοξοθειαζολιδιν-5-υλ)μεθυλ)φαινοξυ) παραγωγα με δραση αναστολης της αυτοταξινης

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group P.L.C., Brentford Substituierte Thiazolidindionderivate

Also Published As

Publication number Publication date
AU2173888A (en) 1989-03-09
ATE186724T1 (de) 1999-12-15
CA1328452C (en) 1994-04-12
EP0842925A1 (en) 1998-05-20
JP2614497B2 (ja) 1997-05-28
JPH09183771A (ja) 1997-07-15
GR3031873T3 (en) 2000-02-29
JP2837139B2 (ja) 1998-12-14
EP0306228A1 (en) 1989-03-08
DE3856378D1 (de) 1999-12-23
KR0164207B1 (ko) 1999-01-15
IE20000683A1 (en) 2002-07-24
JPH10194971A (ja) 1998-07-28
LU90711I2 (fr) 2001-03-05
JPH09183772A (ja) 1997-07-15
KR890005095A (ko) 1989-05-11
JPH09183726A (ja) 1997-07-15
NL300034I1 (nl) 2001-03-01
DK175176B1 (da) 2004-06-21
NZ226027A (en) 1992-03-26
HK1011029A1 (en) 1999-07-02
SG59988A1 (en) 1999-02-22
PT88410B (pt) 1992-10-30
PT88410A (pt) 1989-07-31
JPH10194970A (ja) 1998-07-28
DK490288D0 (da) 1988-09-02
EP0306228B1 (en) 1999-11-17
DE10199003I2 (da) 2003-09-18
NL300034I2 (nl) 2001-05-01
JPH01131169A (ja) 1989-05-24
ES2137915T3 (es) 2000-01-01
CZ391691A3 (en) 1993-03-17
DE10199003I1 (de) 2003-06-12
JP2817840B2 (ja) 1998-10-30
DK490288A (da) 1989-03-05
US5002953A (en) 1991-03-26
AU611938B2 (en) 1991-06-27
DE3856378T2 (de) 2000-05-11

Similar Documents

Publication Publication Date Title
DK200001556A (da) Substituerede thiazolidindionderivater
RU2415846C2 (ru) Производные, имеющие активность агонистов ppar-рецепторов
KR101179087B1 (ko) 인간 단백질 티로신 포스파타아제 억제제 및 이용 방법
KR950702982A (ko) 치환된 티아졸리딘디온 유도체(Substituted Thiazolidinedione Derivatives)
RU2203897C2 (ru) Производные бензамидина, способ их получения, фармацевтическая композиция, способ ее получения и лекарственное средство
KR930702287A (ko) 신규화합물
CA2729557A1 (en) Chemical compounds 251
KR940006590A (ko) 알쯔하이머 질환 치료용 및 혈당저하제로서 유용한 화합물
RU2008117170A (ru) Пиримидинамидные соединения как ингибиторы pgds
KR960704544A (ko) 비인슐린 의존성 당뇨병(niddm)의 개시를 예방 또는 지체시키기 위한 티아졸리딘디온의 용도[use of thiazolidinediones to prevent or delay onset of niddm]
KR930701434A (ko) 옥사졸리딘 디온 유도체
JP2008511683A5 (da)
CZ293392A3 (en) Leucotriene biosynthesis inhibitors
KR910004581A (ko) 신규 화합물들
DE69803750D1 (de) Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
WO2003037894A1 (en) 4-(5-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
KR890003742A (ko) 카르바모일키롤리돈 유도체 및 노인성 치매용 약제
WO1994025026A1 (en) Use of thiazolidinediones for the treatment of atherosclerosis and eating disorders
KR930702288A (ko) 타이졸리딘디온 유도체
UY25227A1 (es) Procedimiento para preparar 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-2,4-tiazolidindiona
US20030149054A1 (en) Novel compounds
ATE269862T1 (de) Substituierte thiazolidinedione und oxazolidinedione mit antidiabetischen, hypolipidämischen und antihypertensiven eigenschaften
ATE310000T1 (de) Ein thiazolidindionderivat und seine verwendung als antidiabetikum
ATE343574T1 (de) Ein thiazolidindionderivat und seine verwendung als antidiabetikum
ZA200504474B (en) 5-Substituted-pyrazine or pyridine glucokinase activators.

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment